Skip to main content
Premium Trial:

Request an Annual Quote

New Products: LifeCodexx's PrenaTest

Premium

GATC Biotech subsidiary LifeCodexx has updated its noninvasive sequencing-based PrenaTest for fetal trisomies so that it can be performed in high-risk pregnancies as early as nine weeks. The company incorporated a technology dubbed QuantYfeX, which it uses to measure the amount of cell-free fetal DNA in the mother's blood. The PrenaTest can be performed when cffDNA is above 4 percent.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.